drugset / Trial / NCT03366272
Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients
Phase 2/3
Completed
348 enrolled
Saarland University
Bristol-Myers Squibb · collabLymphoma Study Association · collabUniversity of Leipzig · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study evaluates the addition of nivolumab to gemcitabine, oxaliplatin plus rituximab in case of B-cell lymphoma
Timeline
- Start
- 2017-12-05
- Primary completion
- 2025-01-15
- Completion
- 2025-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 480 mg | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | — |